流感活动快速上升，奥司他韦、速福达销量上涨明显

Group 1 - The core viewpoint of the articles indicates a significant rise in flu cases across China, with the flu positivity rate nearing 45%, marking an entry into a moderate epidemic level, and some provinces reaching high epidemic levels [1] - The flu peak is generally expected between late December and early January, followed by a decline phase [1] Group 2 - In Suzhou, the flu epidemic has officially begun, with the predominant strain being H3N2, leading to a surge in sales of cold and flu medications [2] - Sales data from Dingdang Kuaiyao shows a notable increase in the sales of antiviral medications, with Oseltamivir's sales rising by 237% and Baloxavir's by 180% over the past week [2] - On Alibaba Health's sales rankings, Oseltamivir capsules sold over 50,000 units, ranking first, while Baloxavir sold over 20,000 units, ranking sixth [2] Group 3 - JD's drug sales platform reported that the sales revenue of antipyretic and analgesic medications in November increased over 13 times compared to October, with some products seeing over 20 times growth [4] - Meituan's data indicates that orders for specific flu medications have more than doubled since November, with Baloxavir increasing by over 110% and Oseltamivir by over 85% compared to the previous month [4] Group 4 - Baloxavir is currently approved only for individuals aged 5 and older, weighing over 20 kg, and there are still restrictions for children under 5 years old [5] - Medical professionals advise that parents should prioritize seeking medical attention for young children with flu symptoms rather than self-medicating, emphasizing the importance of safety in medication use during pregnancy and breastfeeding [5]